title: Neuroprotective effect of geranylgeranylacetone, a noninvasive heat shock protein inducer, on cerebral infarction in rats.
abstract: The present study evaluated the neuroprotective effect of geranylgeranylacetone (GGA), which is known as an antiulcer agent and more recently as a heat shock protein (HSP) inducer, against cerebral infarction induced by permanent left middle cerebral artery (MCA) occlusion. GGA was given orally in various regimens prior to MCA occlusion in rats. Pretreatment with a single oral GGA dose (800 mg/kg) 48 h before ischemia significantly attenuated cerebral infarction volume (81.7+/-18.4 mm3 versus 369.1+/-70.2 mm3; P<.01). A significant increase in HSP70 immunoreactivity was found in the neocortex in GGA-treated animals with or without ischemia. Pretreatment with a single oral dose of GGA provides an important tool for exploring the mechanisms of neuroprotection against cerebral ischemic neuronal damage.
authors.affiliation: Department of Neurosurgery, School of Medicine, Oita University, 1-1, Idaigaoka, Hasama-machi, Oita 879-5593, Japan.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Nagai
authors.forename: Minoru
authors.initials: M
authors.lastname: Fujiki
authors.forename: Ryo
authors.initials: R
authors.lastname: Inoue
authors.forename: Susumu
authors.initials: S
authors.lastname: Uchida
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Abe
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Nuri Eralp
authors.initials: NE
authors.lastname: Cetinalp
mesh_terms: D000818:Animals; D002544:Cerebral Infarction / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004224:Diterpenes / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009460:Neurologic Examination; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D013778:Tetrazolium Salts; D013997:Time Factors
chemical_list: D004224:Diterpenes; D018840:HSP70 Heat-Shock Proteins; D018696:Neuroprotective Agents; D013778:Tetrazolium Salts; C009591:triphenyltetrazolium; C031049:geranylgeranylacetone